MUC1 and rheumatoid arthritis: When 11 patients with RA and 4 patients with RA-ILD were treated with baricitinib for 6 months, a considerable decrease in inflammation was observed in patients with RA-ILD via a reduction in KL-6, which is a biomarker of RA-ILD.